Ligence Heart vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 75/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Ligence Heart

by Ligence

EchoNext

by Pathway Labs

AI Verdict

Both Ligence Heart and EchoNext are AI-powered tools focused on cardiology, specifically aiding in the diagnosis of heart conditions. However, Ligence Heart specializes in automating the analysis and reporting of 2D transthoracic echocardiography, while EchoNext analyzes standard ECGs to detect hidden structural heart disease. Therefore, while both target similar diagnostic goals, they utilize different input data and diagnostic methodologies.

Choose Ligence Heart if…

Choose Ligence Heart if your primary need is to automate and streamline the analysis and reporting of 2D transthoracic echocardiography studies. This tool is ideal for cardiology departments and sonographers looking to enhance diagnostic efficiency, reduce manual measurement variability, and generate comprehensive reports quickly, allowing clinicians to focus more on patient assessment and treatment decisions.

View Ligence Heart →

Choose EchoNext if…

Choose EchoNext if your goal is to leverage standard ECGs for early, widespread screening of hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. This tool is particularly well-suited for broad access in various clinical settings, from major hospitals to community practices, to identify at-risk patients who may require further echocardiographic evaluation, thereby bridging the gap in early detection.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Ligence Heart	EchoNext
Pricing	Contact-for-pricing	Starts at $600/month
Deployment	Cloud-based; on-premise; hybrid	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Ligence Heart

Ligence Heart is designed to be a web-based, out-of-the-box, fully integrated echocardiography analysis suite with an intuitive interface that resembles programs clinicians use daily. It aims to streamline workflow by automating measurements and reporting, reducing manual tracing, and allowing clinicians to focus on patient interaction.

Clinical Value

Ligence Heart

Ligence Heart automates the analysis and reporting of 2D transthoracic echocardiography, enhancing diagnostic efficiency and accuracy for cardiologists and sonographers. Studies have shown it can outperform human measurements in echocardiography and has strong agreement with CMR. EchoNext, while valuable for screening, primarily identifies patients who *should* undergo further echocardiography, rather than providing definitive diagnostic analysis itself.

Pricing & Value

Tie

Ligence Heart's pricing is available upon contact, making a direct comparison difficult. EchoNext offers tiered pricing starting at $600/month, with additional fees for implementation and onboarding, and an annual discount. Without transparent pricing for Ligence Heart, it's not possible to definitively declare a winner in terms of value.

Enterprise Readiness

Ligence Heart

Ligence Heart offers flexible deployment options including cloud-based, on-premise, and hybrid models, and boasts seamless integration with existing hospital systems like PACS, EHR, and RIS. EchoNext is available through the OpenEvidence platform and targets broad access, but its deployment options and integration capabilities are not as extensively detailed as Ligence Heart's.

Innovation

Tie

Both tools demonstrate significant innovation in their respective domains. Ligence Heart automates complex echocardiography analysis, including advanced measurements like strain, and has received multiple FDA clearances. EchoNext is a pioneering AI tool for detecting hidden structural heart disease from standard ECGs, a capability that previously eluded ECGs, and has shown to outperform cardiologists in certain diagnostic scenarios.

Support & Docs

Ligence Heart

Ligence provides an Instructions for Use (IFU) document, offers training videos to operators, and has a clear contact for technical support and security vulnerability reporting. Information regarding specific support and documentation for EchoNext is not readily available in the provided facts or search results.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Ligence Heart	EchoNext
Tool Name	Ligence Heart	EchoNext
Company	Ligence	Pathway Labs
Description	AI-powered web-based platform that automates the analysis and reporting of 2D transthoracic echocardiography, enhancing diagnostic efficiency and accuracy for cardiologists and sonographers.	FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Primary Data Analyzed	2D transthoracic echocardiography imaging data	Standard 12-lead ECGs
Key Detections/Analysis	Automated recognition of echocardiography imaging data, view classification, heart phase prediction, calculation of measurements, report generation, Area, Distance, Doppler, and Volume quantification, Disease recognition (Heart failure, cardiomyopathy, pulmonary hypertension, valvular heart diseases), Automated strain, Spectral and Tissue Doppler measurements.	Detection of hidden structural heart disease, identifies heart failure risk, screens for valve disease, detects pulmonary hypertension indicators.

Videos

Demos, reviews, and walkthroughs featuring Ligence Heart and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

Ligence Heart is designed to integrate seamlessly with existing PACS and EHR systems, automating echocardiography analysis and report generation to streamline workflows for cardiologists and sonographers. EchoNext integrates through the OpenEvidence clinical decision support platform, making its AI-powered ECG analysis accessible to physicians within their existing tools at the point of care.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

Ligence Heart performs automated measurements with non-inferior accuracy compared to a cardiologist and reduces intra-rater variability in measurements. EchoNext has demonstrated high diagnostic accuracy, with an AUROC of 85.2% in internal tests and 78-80% in external validation for detecting structural heart disease, outperforming cardiologists in controlled evaluations.

What is the learning curve for physicians adopting these AI tools?

Ligence Heart is designed with an intuitive interface that resembles programs physicians use daily, aiming for ease of use and minimal learning time. Training videos are also provided to operators. EchoNext is integrated into the OpenEvidence platform, which is already used by many physicians, suggesting a potentially lower learning curve for those familiar with the platform.

What kind of support and resources are available for implementation and ongoing use?

Ligence offers personalized solutions and APIs for integration with unique or in-house software, and provides training videos for operators. For security concerns or vulnerabilities, Ligence provides contact information for their CPO. Pathway Labs, the company behind EchoNext, has secured funding to expand deployment across health systems and grow its clinical and commercial teams, which suggests resources for implementation and ongoing support.

What clinical context is most appropriate for each tool?

Ligence Heart is specifically designed for cardiologists and sonographers to automate the analysis and reporting of 2D transthoracic echocardiography, enhancing efficiency and accuracy in cardiac diagnostics for conditions like heart failure, cardiomyopathy, pulmonary hypertension, and valvular heart diseases. EchoNext analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, making it suitable for broad access from major hospitals to community practices for early screening.

What audit-trail features are available to ensure transparency and accountability in AI-assisted diagnoses?

Ligence Heart's instructions for use mention auditing as part of their post-market follow-up and risk management activities, with reports and related documents updated as needed. The automatically generated measurements and reports from Ligence Heart must be approved by a cardiologist, indicating a human oversight step in the process.

How do these tools support multi-site rollout and standardization of care?

Ligence Heart offers flexible deployment options, including private cloud integration, which can facilitate multi-site rollouts and secure integration into existing clinical workflows. EchoNext has demonstrated consistent performance across diverse patient demographics, clinical contexts, and numerous hospitals, suggesting its suitability for standardization across different care settings.